# Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

> **NCT06441565** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 84 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT06441565
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2025-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441565, "Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06441565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*